Regardless of the presence of HLH/HLH-like systemic illnesses, IST-based regimens could alternatively be considered as first-line therapy for pediatric patients with SPTCL, particularly those with HAVCR2 mutations. The gene discussed is HAVCR2; the disease is subcutaneous panniculitis-like T-cell lymphoma.